GlassScriptPhysician profile
Samuel B Hooks
NPI 1083669535
$6,985.19
in general payments reported to CMS, 2019-2025
34 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $773 · 2021: $1,621 · 2022: $852 · 2023: $672 · 2024: $900 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,300.77 | 2019-2025 | |
| Janssen Biotech, INC. | $1,009.05 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $473.46 | 2019-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $390.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.68 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $360.79 | 2019-2025 | |
| Celgene Corporation | $248.82 | 2021-2023 | Zeposia |
| Covidien LP | $200.77 | 2019 | |
| Ambu INC. | $181.66 | 2020 | |
| Daiichi Sankyo INC. | $155.79 | 2019-2022 | |
| Pfizer INC. | $146.89 | 2019 | |
| Ardelyx, INC. | $138.48 | 2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $120.47 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $82.62 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $82.38 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $78.16 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $72.33 | 2024-2025 | Voquezna |
| Olympus America INC. | $67.43 | 2022-2025 | Evis Exera III Colonovideoscope, Endoclot Sis, Endoclot Phs |
| Conmed Corporation | $57.32 | 2019-2024 | Conmed Hemostasis |
| Ferring Pharmaceuticals INC. | $55.48 | 2020-2023 | Cimzia |
| Redhill Biopharma INC. | $54.68 | 2021-2023 | Aemcolo, Talicia |
| Aimmune Therapeutics, INC. | $47.70 | 2024 | |
| Nestle Healthcare Nutrition INC. | $43.37 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $35.73 | 2021-2022 | |
| Cook Medical LLC | $29.32 | 2023 | Hemospray |
| Shionogi INC | $27.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $26.01 | 2020 | |
| Shire North American Group INC | $23.88 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.17 | 2024 | Quviviq |
| Allergan, INC. | $18.49 | 2020 | |
| Endo Pharmaceuticals INC. | $17.67 | 2019 | |
| Genzyme Corporation | $16.65 | 2022 | |
| Sumitomo Pharma America, INC. | $14.19 | 2025 | Gemtesa |
| Csl Behring | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.